Cancer Treatment Reviews

Papers
(The TQCC of Cancer Treatment Reviews is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Claudins as diagnostic tools and therapeutic targets—Glimpse of the horizon188
Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer179
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)170
The COVID-19 pandemic: An opportunity to rethink and harmonise the frequency of follow-up visits for patients with early stage breast cancer161
Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: A systematic review and updated meta-analysis141
Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms127
Acknowledgement to Reviewers 2021120
Editorial Board117
Editorial Board105
Editorial Board103
Editorial Board101
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review86
Editorial Board81
Editorial Board80
Managing postoperative biochemical relapse in prostate cancer, from the perspective of the Francophone group of Urological radiotherapy (GFRU)76
Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations74
The tumor immune composition of mismatch repair deficient and Epstein-Barr virus-positive gastric cancer: A systematic review73
Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review70
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications69
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer65
Editorial Board60
De-escalating adjuvant therapies in older patients with lower risk estrogen receptor-positive breast cancer treated with breast-conserving surgery: A systematic review and meta-analysis60
Evolution of the HIF targeted therapy in clear cell renal cell carcinoma59
PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives57
The role of transforming growth factor β in upper gastrointestinal cancers: A systematic review57
Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches55
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies53
Proton beam therapy for children and adolescents and young adults (AYAs): JASTRO and JSPHO Guidelines52
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis51
Artificial intelligence for prediction of treatment outcomes in breast cancer: Systematic review of design, reporting standards, and bias51
First line treatment of BRAF mutated advanced melanoma: Does one size fit all?51
Current advances in targeted therapy for metastatic colorectal cancer – Clinical translation and future directions49
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review49
Current state of play for HPV-positive oropharyngeal cancers48
NTRK gene fusion testing and management in lung cancer48
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers45
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review45
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives45
Liquid biopsy after resection of pancreatic adenocarcinoma and its relation to oncological outcomes. Systematic review and meta-analysis45
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice44
Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy43
Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma42
Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants42
Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon42
Radiomics and radiogenomics in head and neck squamous cell carcinoma: Potential contribution to patient management and challenges41
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas39
Systemic therapy for older patients with early breast cancer39
Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification39
GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee38
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis37
Cabozantinib: An evolving therapy for hepatocellular carcinoma37
Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group36
The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer36
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing36
Practical clinical management of ocular adverse events related to Antibody-Drug Conjugates in gynaecological malignancies36
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer36
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in36
Beyond HER2: Targeting the ErbB receptor family in breast cancer35
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials35
Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review34
Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes34
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer33
Precision medicine for multiple myeloma: The case for translocation (11;14)32
Mobile applications for early breast cancer chemotherapy-related symptoms reporting and management: A scoping review32
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer32
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges31
Neurological complications of cancer immunotherapy31
177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers31
Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?31
Local control strategies for management of NSCLC with oligoprogressive disease31
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?30
Systematic review of fetal and placental metastases among pregnant patients with cancer30
Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer30
Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies30
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?30
Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes29
Treatment landscape of metastatic pancreatic cancer29
Comparative analysis of international guidelines on the management of advanced non-functioning well-differentiated pancreatic neuroendocrine tumors29
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?29
Microsatellite instability in Gastric Cancer: Between lights and shadows29
High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review28
Diagnosis and management of bispecific T cell–engaging antibody toxicity: A primer for emergency physicians28
Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic revie28
Editorial Board27
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?27
The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review25
Engineering strategies to optimise adoptive cell therapy in ovarian cancer25
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev.25
Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS –GROUP). Part II25
Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312]25
Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives24
Optimizing care in early phase cancer trials: The role of palliative care24
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project24
Molecular aspects of brain metastases in breast cancer23
Corrigendum to “Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis” [Cancer Treatm. Rev. 93 (2021) 102141]23
If it’s a target, it’s a pan-cancer target: Tissue is not the issue23
How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force23
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer22
Proton pump inhibitors and cancer treatments: Emerging evidence against coadministration22
Locally advanced and metastatic endometrial cancer: Current and emerging therapies22
Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news21
Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies21
Breast reconstruction and radiation therapy: An Italian expert Delphi consensus statements and critical review21
Clinical trial designs for evaluating and exploiting cancer evolution21
Editorial Board20
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches20
Editorial Board20
Compliance to chemoradiation in squamous cell carcinoma of the anus20
Editorial Board20
Editorial Board20
Impact of molecular profiling on the management of patients with myelofibrosis19
Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS – GROUP). Part I19
Outcomes and toxicities of re-irradiation for prostate cancer: A systematic review on behalf of the Re-Irradiation Working Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)19
First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features19
Editorial Board19
Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer19
Chemotherapy in pancreatic ductal adenocarcinoma: When cytoreduction is the aim. A systematic review and meta-analysis19
Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer18
European expert panel consensus on the clinical management of BRAF-mutant metastatic colorectal cancer18
First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers?18
Accelerating drug development in breast cancer: New frontiers for ER inhibition18
Impact of loss of HER2 positivity following neoadjuvant therapy in HER2-positive breast cancer patients on long-term prognosis: A systematic review and meta-analysis18
PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence18
Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations18
0.081378936767578